Drugs / INDATUXIMAB RAVTANSINE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00723359 | Aug 2008 → Apr 2012 | plasma cell myeloma | Biotest Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01638936 | Jul 2012 → Oct 2018 | plasma cell myeloma | Biotest Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT01001442 | Aug 2010 → Jul 2014 | plasma cell myeloma | Biotest Pharmaceuticals Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INDATUXIMAB RAVTANSINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743031 ↗ |
| Known as | BT062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00723359 ↗ |
| Known as | Indatuximab ravtansina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743031 ↗ |
| Action | Deplete | “BT062 is an antibody-drug conjugate designed to bind and destroy Myeloma cells.” NCT01638936 ↗ |
| Route | Intravenous | “intravenous administration” NCT01001442 ↗ |
| Target | SDC1 | “Syndecan-1 binding agent” CHEMBL1743031 ↗ |